
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is expected to see success in developing treatments for a wide range of serious neuromuscular diseases by utilizing its proprietary FORCE platform, with a potential BLA submission for their first commercial product in 3Q27. They have a strong financial position, with a cash runway into 1Q28 and a 12-month price target of $38 per share. However, there are risks, including the need for future fundraising, competition from other companies in the oligonucleotide therapy space, and the potential for slower market penetration.
Bears say
Dyne Therapeutics is a development stage company that currently does not have any products that generate revenue. This, coupled with its high cash burn rate, leads to a negative outlook on the stock. Additionally, the company will likely need to raise more capital in the future, which may dilute the stock and involve restrictive covenants. The success of the company's pipeline is also uncertain and faces competition from larger, more established companies in the gene therapy/oligonucleotide space. Until the company achieves significant milestones, its valuation is difficult to accurately determine, making it a risky investment.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares